Cambridge, Mass.-based Sarepta Therapeutics reported the first known death from its Duchenne muscular dystrophy gene therapy ...

Details of the Edgewise presentations at MDA: Edgewise Industry Forum Edgewise is sponsoring an Industry Forum, “Spotlight on Becker muscular dystrophy: Understanding the lived experience of ...

On the basis of these findings and clinical experience, individuals with Becker muscular dystrophy (BMD) are advised to avoid excess physical exertion. Sveen et al. have performed the first study ...

Edgewise Therapeutics to Present on Sevasemten for the Treatment of Becker Muscular Dystrophy at the 2025 MDA Clinical and Scientific Conference – Company to host an Industry Forum to discuss ...

Edgewise is sponsoring an Industry Forum, "Spotlight on Becker muscular dystrophy: Understanding the lived experience of Becker and clinical advancements with a novel agent." Only conference ...

Title: P10: Prediction of North Star Ambulatory Assessment trajectories in Becker muscular dystrophy: Model development and validation Title: P11: Two-year sevasemten treatment outcomes in Becker ...